Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Ovarian Cancer
Status:
Terminated
Trial end date:
2002-10-18
Target enrollment:
Participant gender:
Summary
Current therapies for Stage III or IV Ovarian Cancer provide very limited benefit to the
patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove
beneficial in the treatment of Stage III or IV Ovarian Cancer.
PURPOSE: This study is being performed to determine the effects (good and bad) that
Antineoplaston therapy has on patients with Stage III or IV Ovarian Cancer.